Staffing decisions

Planning Biomarker Screening and Specimen Workflows in Oncology Trials

Plan oncology biomarker screening with clear specimen, laboratory-report, and eligibility-review handoffs and scoped monitoring responsibilities.

By Lampgen Clinical Research

· Updated

Lampgen biomarker ad shows a conceptual pathology slide carrier, transport case, and report folder linked by a teal ribbon. Headline: The biomarker result starts with the handoff. CTA: Scope CRA support.
AI-generated conceptual editorial illustration; no actual patient, clinical record, study data, facility, or demonstrated result is depicted.
Track the specimen and the report.

Biomarker screening needs a documented route for the specimen and a documented route for the report. Map collection or retrieval, processing, shipment, receipt, laboratory release, and investigator review before the first screening visit.

NCI’s biospecimen resources explain how collection, processing, storage, and associated information can affect research usefulness. The workflow below is an operational planning approach; the current protocol, laboratory manual, consent, and study procedures determine the actual requirements.

Follow the specimen and the report

For the specimen, identify the source, retrieval contact, preparation requirements, shipping process, receiving laboratory, and expected confirmation. For the report, identify where it appears, who checks availability, who reviews it for the study, and where that review is documented.

A specimen arriving at the laboratory does not establish that the investigator has the required result. A report becoming available does not establish that its underlying sample met every study requirement. Record each status distinctly.

Give delays a useful description

  • Unavailable specimen: the requested material has not been located or released.
  • Inadequate specimen: the laboratory has identified a problem that needs a study-directed response.
  • Pending report: testing or report release remains incomplete.
  • Pending review: the report is available but the required study review has not been documented.
  • At-risk screening window: the remaining time requires escalation through the agreed process.

Rehearse the exception before activation

Use a hypothetical referral whose archival tissue is held at another institution. Walk through the request, consent and authorization requirements, shipping arrangements, expected turnaround, and the contact who can address a stalled step. Do not improvise a replacement test or change eligibility outside the approved process.

For a repeat collection, confirm the investigator’s decision and the study’s requirements. Keep the participant informed through the appropriate site team. Practical access issues, such as returning for another procedure or arranging travel, should be identified early enough for the authorized team to consider its options.

Connect monitoring responsibilities to the staffing brief

The CRA can review required site documentation, follow up on open items, and escalate within the monitoring plan. The CTM or designated study lead can coordinate patterns that cross sites or laboratory interfaces. The investigator and designated medical team retain medical and eligibility decisions.

Assess candidates using a comparable specimen or report-delay example. Define the relevant systems, expected follow-up, decision contacts, and review cadence. Measure the process using documented dates and reasons; do not infer a collection-quality problem from a late report alone.

Sources

  1. NCI, Biospecimen Best Practices
  2. ICH E6(R3), monitoring and data responsibilities

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?